Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
about
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaThalidomide in the treatment of cancer cachexia: a randomised placebo controlled trialCurcumin AntiCancer Studies in Pancreatic CancerChemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Systemic Chemotherapy in Advanced Pancreatic CancerNovel agents for advanced pancreatic cancerPerspectives in the treatment of pancreatic adenocarcinomaAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPersonalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatmentGemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysisPredictive modeling of in vivo response to gemcitabine in pancreatic cancerInhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imagingA randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
P2860
Q24240739-0F06A205-AE39-4C03-A955-C4E48AC23E2EQ24245085-28C411D2-4DB1-4EFE-934F-42A7C7FA5A3DQ24627664-93D4A6F2-CCD8-4CFA-A5E8-06318B52E741Q24685678-43F5733B-04EB-442A-AE3F-1A10B3CF6EC6Q26738714-598026B7-0E2B-4C05-B721-90D5769C532DQ26746031-E7F4C24C-2076-4270-B775-C35752A94AE7Q26750440-00FE150F-6C31-4DC7-BB79-F1A20DC3BDC9Q26787087-E223FA06-E14A-479C-AEDF-757AFFA08D8CQ26797248-3F9B90E5-184D-4DC9-A4D3-19C818F7CB1DQ26798674-B0EE03A8-EC09-469C-BD0D-6ABD29AB5A6BQ26828959-696D2E5E-E251-426F-920D-C603977AF77EQ26830913-6FBF7418-EB42-4F3A-A6F2-4D92C8697082Q27021716-55E970BD-E87E-4ADE-B0D8-B6025E613DA5Q28066268-DB58705D-0238-46F7-983E-089F5935ED63Q28074428-3FE167E0-FCC6-46E7-885B-35AE72CD712BQ28487656-4A3E35F1-6816-4F26-A81D-04DCC7F9BBB2Q28533633-B67E621D-5462-46FE-9A99-1D9373588E6BQ30424344-453CDFE6-DD9C-4152-9D90-F5B53F9A48B4Q30477363-3DEFDFDA-A35B-4E01-A072-5533429E105DQ33265964-230C8DB5-BB53-43FF-9540-E447622B4726Q33326148-09D73FBD-D0DF-409C-B38E-61972B12A2A7Q33350085-A9E3C30F-6080-42CD-A439-A88812267935Q33364008-ADCB5478-7710-4690-B6EE-F7072B3F2052Q33365031-0BDAAE84-5AB6-4CDB-9ACA-5E2D1649E039Q33366682-E8B19F7B-16E4-4FD1-87CD-63C45EA97DD2Q33370390-B5E8EF97-A257-4A1E-9C5D-66725C449AA3Q33370969-4CA2F0E5-5573-4001-95E8-4BDBD4563941Q33371000-BDD3D6A8-E3B5-4C45-B710-089532CC6B40Q33371225-61A153F2-BEFC-4CA6-BA47-637F0394B2FDQ33373308-E42BEB6F-6491-4F2F-B4FF-C3F5BAC270EAQ33374300-D2F07F9E-2A74-4974-8983-11A047D5F712Q33377760-3CEB8B32-69F1-4F3D-8912-6D4A67692083Q33380084-66244A85-2A3A-454C-A929-C6C8E3128E02Q33380878-2809867B-A0A5-42E9-A264-DB2019B6AEF4Q33382236-FF3C435E-3B2C-4D71-A716-EF039AC6FB78Q33394505-0C697946-2528-4246-BCFE-C74F9D68FFF1Q33394729-E1F33109-3C2A-4DDB-B5DE-0B633D4961F4Q33395577-DA0E1761-A704-4165-8121-56CC1A0C0812Q33399212-4624436F-8132-475F-8E63-B38179D0751FQ33400095-271BEB6C-FED8-4B65-AD6F-83412CAD8A87
P2860
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@ast
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@en
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@nl
type
label
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@ast
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@en
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@nl
prefLabel
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@ast
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@en
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@nl
P2093
P356
P1476
Phase III study of gemcitabine ...... ve Oncology Group Trial E2297.
@en
P2093
Al Bowen Benson
Daniel G Haller
James P Thomas
John W Kugler
Jordan D Berlin
Paul Catalano
P304
P356
10.1200/JCO.2002.11.149
P407
P577
2002-08-01T00:00:00Z